What’s New with Innocoll?
Catch up on the latest developments.
DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)
Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll® (bupivacaine hydrochloride) Implant
Anthony Galdi Appointed Chief Commercial Officer of Innocoll
Louis Pascarella Appointed Chief Executive Officer of Innocoll